**Botulinum toxin- how a poison turned to a fascinating ally against an old adversary**

**Toxina botulínica- de como um veneno transformou-se num fascinante aliado contra um velho adversário**

*Elizabeth M. A. Barasnevicius Quagliato*

 **The clinical features of** [**dystonia**](http://www.movementdisorders.org/disorders/dystonia.php) **were first reported in 1911, when Oppehneim1 and Flatau2 described some Jewish children affected by a syndrome, that was retrospectively considered to represent familial cases of DYT1 dystonia. In 1975 it was recognized that the dystonia phenotype also encompasses poorly-progressive focal and segmental cases with onset in adulthood, such as blepharospasm, cervical dystonia (CD) and writer’s cramp3. A modern definition of dystonia was worded some years later, in 19844,5.**

 **CD is the most common form of focal dystonia and its prevalence is estimated to be 11.5 cases per 100,000 individuals. CD is characterized by involuntary contractions of cervical region muscles, leading to awkward posture of the head and neck. Most of the cases have idiopathic origin6 .**

 **In this volume of *Arquivos de Neuropsiquiatria*, Werle el al published the article “The physical, social and emotional aspects are the most affected in the quality of life (QoL) of the patients with cervical dystonia”, showing how painful and distressing this disease can be without the treatment effect. Among those seventy Brazilian patients, 84% had pain, disabling in half of them. The vast majority showed difficulty in keeping up with professional and personal demands, felt uneasy in public and suffered depression. The greater the disability, pain and severity of dystonia, the worse the QoL7.**

 **Botulinum toxin (BT) poisoning has afflicted mankind through since a long time ago. The physician and poet Justinus Kerner published the first accurate descriptions of food-borne botulism in 1822, and also postulated that the toxin might be used for treatment purposes. In 1895, in the Belgian village of Ellezelles, an outbreak of botulism led to the discovery by Emile Pierre van Ermengem of the pathogen *Clostridium Botulinum*, the anaerobic bacterium that produces the neurotoxin. Alan B. Scott and Edward J. Schantz, in the 1970s, were the modern pioneers of botulinum toxin (BT) treatment to correct strabismus8.**

 **The molecular biology cleared about the precise *Clostridium Botulinum toxin* mechanism, showing that BT acts in the cytosol of nerve endings to cleave the SNAP-25 protein, that mediates the docking and fusion of neurotransmitter-containing vesicles to the presynaptic membrane. This cleavage prevents exocytosis of acetylcholine from the presynaptic terminal of neuromuscular junctions, resulting in a temporary, reversible block of the motor fibers and weakened muscle contraction. This is the rationale for its use in dystonia treatment. To date, BT has been used to treat a wide variety of diseases associated with muscular hyperactivity, glandular hypersecretions and pain9,10.**

 **In Brazil, this friendly poison has been employed in many neurologic conditions since 1991, improving patient’s lives and turned out a precious tool for skilled doctors. Many Brazilian articles has been published and more and more doctors are familiarized its indications, injection technics and results11,12.**

 **BT injections continue, aside oral medication, and, more recently, deep brain stimulation, as the current mainstays of treatment for dystonia. In addition, physical and other supportive therapies may help prevent further complications, as contractures, and improve function. Evidence-based medical treatment of dystonia enhances BT impact on QoL and motor aspects on those patients13,14.**

**References:**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **Oppenheim H. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (Dysbasia lordotica progressiva, Dystonia musculorum deformans). Neurologische Centralblatt 1911;30:1090-1107.**
2. [**Eldridge R**](http://www.ncbi.nlm.nih.gov/pubmed?term=Eldridge%20R%5BAuthor%5D&cauthor=true&cauthor_uid=782202)**. Edward Flatau, Wladyslaw Sterling, Torsion spasm in Jewish children, and the early history of human genetics. Adv Neurol. 1976;14:105-114.**
3. **Marsden CD. Dystonia: the spectrum of the disease. Res Publ Assoc Res Nerv Ment Dis 1976;55:351-367.**
4. **Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths; 1987. p. 332-358.**
5. [**Bragg DC**](http://www.ncbi.nlm.nih.gov/pubmed?term=Bragg%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=24744022)**1,** [**Sharma N**](http://www.ncbi.nlm.nih.gov/pubmed?term=Sharma%20N%5BAuthor%5D&cauthor=true&cauthor_uid=24744022)**. Update on treatments for dystonia. Curr Neurol Neurosci Rep. 2014 Jun;14(6):454. doi: 10.1007/s11910-014-0454-8.**
6. **Camfield L, Ben-Shlomo Y, Warner TT. Impact of cervical dystonia in quality of life. Mov Disord 2002;17:838-841.**
7. **Werle WR, TakedaSYM, ZontaMB GuimarãesATB,TeiveHAG. The physical, social and emotional aspects are the most affected in the quality of life of the patients with cervical dystonia. DOI: 10.1590/0004-282X20140044**
8. [**Erbguth FJ**](http://www.ncbi.nlm.nih.gov/pubmed?term=Erbguth%20FJ%5BAuthor%5D&cauthor=true&cauthor_uid=15027048)**. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004 Mar;19 Suppl 8:S2-6.**
9. **Lim EC, Seet RC.** [**Use of botulinum toxin in the neurology clinic.**](http://www.ncbi.nlm.nih.gov/pubmed/21045798) **Nat Rev Neurol. 2010 Nov;6(11):624-636.**
10. **Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB.** [**International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction.**](http://www.ncbi.nlm.nih.gov/pubmed/20633176) **Eur J Neurol. 2010 Aug;17 Suppl 2:1-8.**
11. **[Quagliato EM](http://www.ncbi.nlm.nih.gov/pubmed?term=Quagliato%20EM%5BAuthor%5D&cauthor=true&cauthor_uid=19959960)AB,** [**Carelli EF**](http://www.ncbi.nlm.nih.gov/pubmed?term=Carelli%20EF%5BAuthor%5D&cauthor=true&cauthor_uid=19959960)**,** [**Viana MA**](http://www.ncbi.nlm.nih.gov/pubmed?term=Viana%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=19959960)**. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010;33(1):22-26.**
12. **QueirozMR, ChienHF, Barbosa ER.. Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital Arq Neuropsiquiatr 2011;69(6):900-904.**
13. [**Queiroz MA**](http://www.ncbi.nlm.nih.gov/pubmed?term=Queiroz%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=23402680)**,** [**Chien HF**](http://www.ncbi.nlm.nih.gov/pubmed?term=Chien%20HF%5BAuthor%5D&cauthor=true&cauthor_uid=23402680)**,** [**Sekeff-Sallem FA**](http://www.ncbi.nlm.nih.gov/pubmed?term=Sekeff-Sallem%20FA%5BAuthor%5D&cauthor=true&cauthor_uid=23402680)**,** [**Barbosa ER**](http://www.ncbi.nlm.nih.gov/pubmed?term=Barbosa%20ER%5BAuthor%5D&cauthor=true&cauthor_uid=23402680)**. Physical therapy program for cervical dystonia: a study of 20 cases. Funct Neurol 2012 Jul-Sep;27(3):187-92.**
14. [**Bragg DC**](http://www.ncbi.nlm.nih.gov/pubmed?term=Bragg%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=24744022)**1,** [**Sharma N**](http://www.ncbi.nlm.nih.gov/pubmed?term=Sharma%20N%5BAuthor%5D&cauthor=true&cauthor_uid=24744022)**. Update on treatments for dystonia. Curr Neurol Neurosci Rep. 2014;14(6):454. doi: 10.1007/s11910-014-0454-8.**